{"classes":[{"categories":[{"measurements":[{"comment":"OS data are interim at data cutoff, with only 3 events in the study treatment phase (median follow-up 14.2 mos)","groupId":"OG000","lowerLimit":"17.710","upperLimit":"NA","value":"17.71"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"}],"units":"Participants"}],"description":"The time from the start of study treatment to death due to any cause. OS was censored at the last date that the participant was known to be alive for participants who were alive at the time of analysis and for participants who were lost to follow-up before death was documented.","dispersionType":"95% Confidence Interval","groups":[{"description":"Lenalidomide 25 mg orally once daily for 21 days in each 28-day cycle until progressive disease or lenalidomide discontinuation for any reason.\n\nDexamethasone 40 mg orally once daily on Days 1, 8, 15 and 22 in each 28-day cycle until progressive disease or lenalidomide discontinuation for any reason.","id":"OG000","title":"Lenalidomide Plus Dexamethasone"}],"paramType":"MEDIAN","populationDescription":"Efficacy Evaluable (EE) Population consists of all participants who met the protocol requirements (all eligibility criteria) and were evaluated after receiving at least one dose of study drug.","reportingStatus":"POSTED","timeFrame":"From the first dose of study drug treatment until the data cut-off date of 15 July 2014. Median follow up is 14.2 months","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"months"}